Genotype-Based Molecular Mechanisms in Alport Syndrome
- PMID: 39899372
- PMCID: PMC12147967
- DOI: 10.1681/ASN.0000000647
Genotype-Based Molecular Mechanisms in Alport Syndrome
Abstract
Alport syndrome is an inherited disorder characterized by kidney disease, sensorineural hearing loss, and ocular abnormalities. Alport syndrome is caused by pathogenic variants in COL4A3 , COL4A4 , or COL4A5 , which encode the α 3, α 4, and α 5 chains of type 4 collagen that forms a heterotrimer expressed in the glomerular basement membrane. Knowledge of its genetic basis has informed the development of different models in dogs, mice, and rats that reflect its autosomal and X-linked inheritance patterns as well as different mutation types, including protein-truncating and missense variants. A key difference between these two types is the synthesis of α 3 α 4 α 5(IV), which is not made in autosomal Alport syndrome (two pathogenic variants in trans or biallelic) or male patients with X-linked Alport syndrome due to protein-truncating variants. By contrast, α 3 α 4 α 5(IV) is synthesized in Alport syndrome because of missense variants. For missense variants, in vitro studies suggest that these cause impaired type 4 collagen trafficking and endoplasmic reticulum stress. For protein-truncating variants, knockout models suggest that persistence of an immature α 1 α 1 α 2(IV) network is associated with biomechanical strain, which activates endothelin-A receptors leading to mesangial filopodia formation. Moreover, studies suggest that activation of collagen receptors, integrins and discoidin domain receptor 1, play a role in disease propagation. In this review, we provide an overview of how these genotype-phenotype mechanisms are key for a precision medicine-based approach in the future.
Keywords: alport syndrome; molecular genetics.
Copyright © 2025 by the American Society of Nephrology.
Conflict of interest statement
Disclosure forms, as provided by each author, are available with the online version of the article at
Similar articles
-
Potential Renal Damage Biomarkers in Alport Syndrome-A Review of the Literature.Int J Mol Sci. 2022 Jun 30;23(13):7276. doi: 10.3390/ijms23137276. Int J Mol Sci. 2022. PMID: 35806283 Free PMC article.
-
Glomerular basement membrane deposition of collagen α1(III) in Alport glomeruli by mesangial filopodia injures podocytes via aberrant signaling through DDR1 and integrin α2β1.J Pathol. 2022 Sep;258(1):26-37. doi: 10.1002/path.5969. Epub 2022 Jun 22. J Pathol. 2022. PMID: 35607980 Free PMC article.
-
A novel COL4A5 splicing mutation causes alport syndrome in a Chinese family.BMC Med Genomics. 2024 Apr 26;17(1):108. doi: 10.1186/s12920-024-01878-8. BMC Med Genomics. 2024. PMID: 38671472 Free PMC article.
-
Diagnosis, management and treatment of the Alport syndrome - 2024 guideline on behalf of ERKNet, ERA and ESPN.Nephrol Dial Transplant. 2025 May 30;40(6):1091-1106. doi: 10.1093/ndt/gfae265. Nephrol Dial Transplant. 2025. PMID: 39673454 Free PMC article.
-
Alport syndrome and Alport kidney diseases - elucidating the disease spectrum.Curr Opin Nephrol Hypertens. 2024 May 1;33(3):283-290. doi: 10.1097/MNH.0000000000000983. Epub 2024 Mar 13. Curr Opin Nephrol Hypertens. 2024. PMID: 38477333 Free PMC article. Review.
References
-
- Kashtan CE. Alport syndrome, In: GeneReviews® [Internet]. University of Washington, Seattle; 1993. Accessed January 13, 2025. https://pubmed.ncbi.nlm.nih.gov/20301386/
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources